Patents:
Biotinylated Compositions
Patent number: 8669236
Abstract: Novel biotinylated composition comprising a nucleic acid, e.g. siRNA, that are useful for targeting therapeutic and imaging agents to sites of infection and tumors are disclosed.
Type: Grant
Filed: May 12, 2006
Date of Patent: March 11, 2014
Assignees: The General Hospital Corporation, Children's Medical Center Corporation
Inventors: David R. Elmaleh, Bruce R. Zetter, Earl Weinstein, Jacqueline Banyard Bhisitkul
Novel Biotinylated Compositions
Publication number: 20090220433
Abstract: Novel biotinylated composition comprising a nucleic acid, e.g. siRNA, that are useful for targeting therapeutic and imaging agents to sites of infection and tumors are disclosed.
Type: Application
Filed: May 12, 2006
Publication date: September 3, 2009
Applicants: The General Hospital Corporation, Children's Medical Center Corporation
Inventors: David R. Elmaleh, Bruce R. Zetter, Earl Weinstein, Jacqueline Banyard Bhisitkul
Methods to Predict and Prevent Resistance to Taxoid Compounds
Publication number: 20160011211
Abstract: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided.
Type: Application
Filed: September 25, 2015
Publication date: January 14, 2016
Inventors: Bruce R. Zetter, Sabarni K. Chatterjee
Methods to Predict and Prevent Resistance to Taxoid Compounds
Publication number: 20090312405
Abstract: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided.
Type: Application
Filed: November 17, 2006
Publication date: December 17, 2009
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Sabarni K. Chatterjee
Methods to Predict and Prevent Resistance to Taxoid Compounds
Patent number: 9151758
Abstract: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided.
Type: Grant
Filed: February 24, 2012
Date of Patent: October 6, 2015
Assignee: Children'Medical Center Corporation
Inventors: Bruce R. Zetter, Sabarni K. Chatterjee
Methods to Predict and Prevent Resistance to Taxoid Compounds
Patent number: 8148086
Abstract: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided.
Type: Grant
Filed: November 17, 2006
Date of Patent: April 3, 2012
Assignee: Children's Medical Center Corporatioin
Inventors: Bruce R. Zetter, Sabarni K. Chatterjee
Methods to Predict and Prevent Resistance to Taxoid Compounds
Publication number: 20130028885
Abstract: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided.
Type: Application
Filed: February 24, 2012
Publication date: January 31, 2013
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Sabarni K. Chatterjee
Methods For Diagnosis and Prognosis of Epithelial CancersPublication number: 20170023574
Abstract: The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.
Type: Application
Filed: February 19, 2016
Publication date: January 26, 2017
Inventors: Bruce R. Zetter, Adam S. Feldman, W. Scott McDougal
Methods of Diagnosis and Prognosis of Epithelial Cancers
Publication number: 20090239245
Abstract: The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.
Type: Application
Filed: January 30, 2006
Publication date: September 24, 2009
Inventors: Bruce R. Zetter, Adam S. Feldman, W. Scott McDougal
Methods for Diagnosis and Prognosis of Cancer
Publication number: 20170184600
Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
Type: Application
Filed: August 9, 2016
Publication date: June 29, 2017
Inventors: BRUCE R. ZETTER, Lere Bao, Jacqueline Banyard
Methods for Diagnosis and Prognosis of Epithelial Cancers
Publication number: 20150093767
Abstract: The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.
Type: Application
Filed: October 1, 2014
Publication date: April 2, 2015
Inventors: Bruce R. Zetter, Adam S. Feldman, Scott W. McDougal
Methods for Diagnosis and Prognosis of Epithelial Cancers
Publication number: 20090136489
Abstract: We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment of cancer, the use of antizyme inhibitor for the diagnosis and prognosis of cancer, and methods for identifying novel cancer treatments.
Type: Application
Filed: December 5, 2008
Publication date: May 28, 2009
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventors: Bruce R. ZETTER, Sonia KIM, Ursula MANGOLD
Method for Diagnosis and Prognosis of Epithelial Cancers
Patent number: 8685659
Abstract: The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.
Type: Grant
Filed: January 30, 2006
Date of Patent: April 1, 2014
Assignees: Children's Medical Center Corporation, The General Hospital Corporation
Inventors: Bruce R. Zetter, Adam S. Feldman, W. Scott McDougal
Implantable Chemoattractant System
Patent number: 4732155
Abstract: A system for providing sustained prolonged release of a chemoattractant to a surrounding biological medium which contains cells responsive to the chemoattractant. The system consists of a biocompatible, non-inflammatory body, which sequesters the chemoattractant and allows sustained prolonged release of the chemoattractant from at least one part of the body. A cell trap is positioned adjacent to the releasing portion of the body, so that the released chemoattractant is transmitted through the trap and attracted cells are trapped in it.
Type: Grant
Filed: August 27, 1985
Date of Patent: March 22, 1988
Assignee: The Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Robert S. Langer
Diagnosis and Treatment of Taxane-Resistant Cancers
Patent number: 9687467
Abstract: Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof.
Type: Grant
Filed: April 4, 2012
Date of Patent: June 27, 2017
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Amy Holleman, Ivy Chung
Cancer Diagnostic Assay
Patent number: 4359527
Abstract: In vitro cancer diagnostic assay comprising providing a substratum coated with a layer of visible particles susceptible to ingestion by capillary endothelial cells, plating such cells onto the substratum, allowing the cells to adhere, incubating the cells with a test sample, measuring the area of the visible particle-depleted phagokinetic track left by at least one of the cells, and comparing that area to the track area left by a control cell, a comparatively larger test track area indicating the presence in the test sample of a factor associated with cancer cells.
Type: Grant
Filed: October 27, 1980
Date of Patent: November 16, 1982
Assignee: The Children's Hospital Medical Center
Inventor: Bruce R. Zetter
Methods for Diagnosis and Prognosis of Cancer
Patent number: 7993863
Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
Type: Grant
Filed: March 18, 2003
Date of Patent: August 9, 2011
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
Diagnosis and Treatment of Taxane-Resistant Cancers
Publication number: 20140329879
Abstract: Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof.
Type: Application
Filed: April 4, 2012
Publication date: November 6, 2014
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Amy Holleman, Ivy Chung
Human Thymosin, Beta15 Gene, Protein and Uses Thereof
Publication number: 20040101910
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr; 15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr; 15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Application
Filed: December 3, 2003
Publication date: May 27, 2004
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Methods and Diagnosis and Prognosis of Epithelial Cancers
Publication number: 20120115134
Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
Type: Application
Filed: July 12, 2011
Publication date: May 10, 2012
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
Antibodies Specific For Human Thymosin &bgr;15 Protein and Uses Thereof
Patent number: 6300479
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Grant
Filed: August 6, 1999
Date of Patent: October 9, 2001
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Thymosin &bgr;-15 Promoter and Uses Thereof
Patent number: 6489463
Abstract: The present invention provides a thymosin &bgr;15 promoter. The promoter comprises the nucleotide sequence of SEQ ID NO:1 or a fragment thereof capable of expressing an operably linked DNA. A DNA sequence having nucleotides −400 to +1 of FIG. 1 is a preferred fragment. The invention also provides novel assays for identifying compounds useful in the treatment of malignancies involving modulation of thymosin &bgr;15 expression, e.g., breast, pancreas and prostate cancer. The invention further provides a method of human gene therapy for treating malignancies involving up-regulation of thymosin &bgr;15 expression.
Type: Grant
Filed: April 13, 2000
Date of Patent: December 3, 2002
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Human Thymosin .beta.15
Patent number: 5721337
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Grant
Filed: February 14, 1997
Date of Patent: February 24, 1998
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Human Thymosin Beta15 Gene, Protein and Uses Thereof
Publication number: 20020183496
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Application
Filed: June 5, 2001
Publication date: December 5, 2002
Applicant: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Human Thymosin .beta.15 Gene, Protein and Uses Thereof
Patent number: 6017717
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Grant
Filed: April 29, 1998
Date of Patent: January 25, 2000
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Human Thymosin .beta.15 Gene, Protein and Uses Thereof
Patent number: 5831033
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Grant
Filed: September 17, 1997
Date of Patent: November 3, 1998
Assignee: Children's Medical Center of Boston
Inventors: Bruce R. Zetter, Lere Bao
Method for Diagnosis of Cancer
Patent number: 6150117
Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.
Type: Grant
Filed: August 18, 1998
Date of Patent: November 21, 2000
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Human Thymosin .beta. 15 Gene, Protein and Uses Thereof
Patent number: 5663071
Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is directed to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
Type: Grant
Filed: June 17, 1996
Date of Patent: September 2, 1997
Assignee: Children's Medical Center Corporation
Inventors: Bruce R. Zetter, Lere Bao
Methods for Diagnosis and Prognosis of Cancer
Publication number: 20060105343
Abstract: We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.
Type: Application
Filed: January 7, 2004
Publication date: May 18, 2006
Applicant: Children's Medical Center Corporation
Inventors: Bruce Zetter, Lloyd Hutchinson, Lere Bao
Method for Prognosis of Prostate Cancer
Patent number: 5858681
Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.
Type: Grant
Filed: June 17, 1996
Date of Patent: January 12, 1999
Assignee: Children's Medical Center
Inventors: Bruce R. Zetter, Lere Bao